Mucolipidoses

Mucolipidoses are a group of rare lysosomal storage disorders caused by defects in the targeting and trafficking of lysosomal enzymes, leading to the accumulation of storage material in lysosomes throughout multiple tissues. The main forms are mucolipidosis II (I-cell disease), mucolipidosis III (alpha/beta and gamma forms), and mucolipidosis IV. ML II and ML III result from mutations in GNPTAB or GNPTG, which encode subunits of N-acetylglucosamine-1-phosphotransferase; ML IV stems from MCOLN1 mutations encoding the lysosomal cation channel mucolipin-1.

Pathophysiology involves impaired tagging of acid hydrolases with mannose-6-phosphate, reducing delivery of these enzymes to lysosomes and increasing their secretion outside the cell. This leads to widespread lysosomal dysfunction and multisystem storage, with severity varying by subtype.

Clinical features vary by form. ML II typically presents in infancy with growth retardation, coarse facial features, skeletal abnormalities (dysostosis multiplex), hepatosplenomegaly, and severe psychomotor impairment. ML III is generally milder and later-onset, with joint stiffness, bone deformities, and organomegaly. ML IV often shows later onset with neurodevelopmental issues and ophthalmologic problems such as corneal clouding and progressive retinal degeneration, along with airway and gastrointestinal involvement. Hearing loss is common in several forms.

Diagnosis is suggested by elevated plasma lysosomal enzyme activities and confirmed by genetic testing for GNPTAB, GNPTG, or MCOLN1 mutations; fibroblast or leukocyte enzyme assays can support the diagnosis. There is no disease-specific cure; management is supportive and multidisciplinary, focusing on mobility, respiration, nutrition, and vision/hearing care. Prognosis ranges from severe infantile disease (ML II) to variable outcomes in ML III and ML IV.